Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature.

摘要: In the past, osteonecrosis of jaw (ONJ) was generally reported with bisphosphonate drugs; hence, term BRONJ (bisphosphonate-related jaw) initially proposed. This followed by ARONJ (antiresorptive jaw). More recently, other novel medications such as vascular endothelial growth factor (VEGF) inhibitors, tyrosine kinase inhibitors and humanised antibodies that affect osteoclastic action have been to initiate ONJ in several cases. For this reason, 2014, American Association Oral Maxillofacial Surgeons (AAOMS) changed MRONJ - medication-related jaw. The review primarily focuses on associated emerging therapies for management bone disorders. article sheds some light risk factors predispose dental patients development osteonecrosis, mechanisms drug MRONJ, potential treatment regimes patients. current noted incidence is significant new therapeutic agents discussed. Therefore, optimised patient care, pharmacovigilance essential professionals.